Application of chiral oxazoline copper complex

文档序号:1608643 发布日期:2020-01-10 浏览:16次 中文

阅读说明:本技术 一种手性噁唑啉铜配合物的用途 (Application of chiral oxazoline copper complex ) 是由 罗梅 李国雄 谢蓝 于 2019-10-17 设计创作,主要内容包括:一种由以下化学式所示的双{2-[4(R)-苯基-4,5-二氢化]-2-噁唑啉基}苯酚铜配合物的用途是作为催化剂在二苯亚胺与三甲基硅腈的反应中及二苯甲酮腙的缩合反应显示了较好的催化性能,其转化率分别达68%及99%;该手性配合物(I)在多种癌细胞如:肺癌(A549)、白血病细胞(HB-60)及肝癌细胞(SMMC-7721)试验中均显示出较强的抑制活性。该配合物的化学式如下:<Image he="406" wi="700" file="DDA0002237432420000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(Bis {2- [4(R) -phenyl-4, 5-dihydro-structure represented by the following chemical formula]The application of the-2-oxazolinyl } phenol copper complex is that the copper complex is used as a catalyst to show better catalytic performance in the reaction of diphenylimine and trimethylsilonitrile and the condensation reaction of benzophenone hydrazone, and the conversion rates of the copper complex respectively reach 68% and 99%; the chiral complex (I) is useful in a variety of cancer cells such as: lung cancer (A549) and leukemiaThe leukemia cell (HB-60) and the liver cancer cell (SMMC-7721) show stronger inhibitory activity in the test. The chemical formula of the complex is as follows:)

1. Use of a copper complex of bis {2- [4(R) -phenyl-4, 5-dihydro ] -2-oxazolinyl } phenol of the formula and unit cell parameters: the compound is used as a catalyst in the reaction of diphenylimine and trimethylsilonitrile and the condensation reaction of benzophenone hydrazone, shows better catalytic performance, the conversion rate of the compound respectively reaches 68 percent and 99 percent, and the chemical formula of the compound is as follows:

Figure FDA0002237432390000011

the unit cell parameters are as follows: MoK alpha rays monochromatized with a graphite monochromator on an Oxford X-ray single crystal diffractometer at a temperature of 273(2) k

Figure FDA0002237432390000012

2. the application of the chiral complex (I) is characterized in that: it is found in a variety of cancer cells such as: : the lung cancer (A549), the liver cancer (SMMC-7721) and the leukemia (HL-60) all show stronger inhibitory activity in the test.

one, the technical field

The invention relates to a metal organic coordination compound (complex) and a preparation method thereof, in particular to a nitrogen-containing oxazoline metal organic complex and a preparation method thereof, and specifically relates to a copper complex of chiral oxazoline and a synthesis method thereof.

Second, background Art

With the development of organic chemistry, the application of metal organic compounds in organic synthesis is becoming wider and wider, which is one of the very active fields in organic chemistry at present, and has been widely applied to organic synthesis reactions. The asymmetric synthetic reactions catalyzed by chiral ligands and transition metal complexes, which occurred in the late 60 s of the 20 th century, have greatly accelerated the study of chiral drugs. The important content of the chemical catalytic asymmetric synthesis method is the design of chiral ligand and metal-containing catalyst, so that the reaction has high efficiency and high enantioselectivity. In recent years, the chiral bisoxazoline ligand-copper metal complex obtains better catalytic effect in the field of asymmetric catalysis.

Reference documents:

1.Evans,David A.;Rovis,Tomislav;Johnson,Jeffrey S.Pure and AppliedChemistry(1999),71(8),1407-1415.

2.Li,Xin;Cun,Lin-Feng;Gong,Liu-Zhu;Mi,Ai-Qiao;Jiang,Yao-Zhong,Tetrahedron:Asymmetry(2003),14(24),3819-3821.

3.Evans,David A.;Shaughnessy,Eileen A.;Barnes,David M.Tetrahedron Letters(1997),38(18),3193-3194.

third, the invention

The invention aims to provide a Cu-N metal organic complex applied to the field of catalysis, and a copper complex which takes ortho-hydroxy oxazoline as a ligand and synthesizes chiral bisoxazoline is selected as a technical problem to be solved.

The chiral bisoxazoline copper complex is a complex which is prepared from o-hydroxybenzonitrile, D-phenylglycinol and copper acetate monohydrate and is shown by the following chemical formula:

Figure BDA0002237432400000011

chemical name: the bis {2- [4(R) -phenyl-4, 5-dihydro ] -2-oxazolinyl } phenol copper complex is called complex (I) for short.

The complex shows better catalytic performance in the condensation reaction of benzophenone imine, trimethylsilonitrile and benzophenone hydrazone, and the conversion rates of the complex respectively reach 68% and 99%.

The synthesis method comprises the steps of synthesis and separation, wherein 55.8 mol% of copper acetate or copper chloride is used as a catalyst for the synthesis, 15.1mmol of o-hydroxybenzonitrile and 3.8g of D-phenylglycinol are used as a solvent, 50mL of chlorobenzene is used for reflux reaction for 72 hours, purification is carried out, namely, the chlorobenzene is removed after the reaction is finished, chloroform is used for extraction after water is added for dissolution, and column chromatography is used for purification after an extraction phase is subjected to desolventization; eluting with petroleum ether and dichloromethane, separating by column chromatography, and naturally volatilizing the second component to obtain chiral bisoxazoline copper complex single crystal.

The synthesis reaction is as follows:

the synthesis method can obtain the target product in one step, and has simple process and convenient operation.

Description of the drawings

FIG. 1 is an X-ray diffraction analysis chart of a copper bis {2- [4(R) -phenyl-4, 5-dihydro ] -2-oxazolinyl } phenol complex.

Fifth, detailed description of the invention

Adding 25.7mmol of copper acetate monohydrate or copper chloride dihydrate, 50mL of chlorobenzene, 1.7966g of o-hydroxybenzonitrile and 3.8g of D-phenylglycinol into a 100mL two-mouth bottle, refluxing the mixture at high temperature for 72h, stopping the reaction, leaching the mixture with petroleum ether and dichloromethane, separating by column chromatography, and naturally volatilizing the final components to obtain a complex single crystal, wherein the yield is 65% and 85%, and m.p.:>200℃,[a]5 D=+235.7°(c=0.0488,CH3OH), elemental analysis: test values are: 66.22 percent of C, 4.39 percent of H and 5.26 percent of N; calculated values: 66.72%, 4.44%, N, 5.18%; IR (KBr) 3439,3025, 2967,2902, 1617,1583,1541,1475,1447,1394,1349, 1266,1155,1077,1030,949,935,855,755,695,666,574,533, 414;

the complex crystal data are as follows:

Figure BDA0002237432400000022

typical bond length data for crystals:

Figure BDA0002237432400000032

typical bond angle data for crystals:

Figure BDA0002237432400000042

Figure BDA0002237432400000051

condensation reaction application of benzophenone imine and trimethylsilonitrile

Figure BDA0002237432400000052

Weighing 0.025mL of benzophenone imine and 0.2mL of trimethylsilonitrile, placing the benzophenone imine and the trimethylsilonitrile into a 25mL flask, adding 0.027g of 2mL of THF and complex I, stirring the mixture for 26 hours at normal temperature, taking a small amount of sample for nuclear magnetic detection, wherein the conversion rate is 68%;1H NMR(600MHz,CDCl3,27℃)δ7.23–7.59(m,10H),4.10(s,2H)。

condensation reaction application of benzophenone hydrazone

Figure BDA0002237432400000061

Weighing 0.084g of benzophenone hydrazone, placing the benzophenone hydrazone in a 25mL small flask, adding 2mL of THF and a compound I0.0232g, stirring the mixture for 26 hours at normal temperature, and taking a small amount of sample for nuclear magnetic detectionConversion rate of>99%;1H NMR(600MHz,CDCl3,27℃),δ7.50–7.44(m,4H),7.43–7.36(m,6H),7.36–7.25(m,10H);13C NMR(100MHz,CDCl3)δ158.93,138.20,135.56,129.60,129.34,128.68,128.66,128.04,127.88.;IR:3422,3057,1664,1622,1491,1444,1321,1278,1176,1076,1028,956,914,767,694,655。

Application of anticancer activity

The invention designs a synthesized platinum complex according to the structure of an active natural product in various cancer cells such as: the compounds of the invention all show strong inhibitory activity in lung cancer, liver cancer and leukemia tests, therefore, the compounds of the invention are expected to be used for treating various cancers, and the test results of part of anticancer activities of the compounds of the invention are shown in table 1:

TABLE 1 data for the anticancer activity of copper complexes (I)

Figure BDA0002237432400000062

9页详细技术资料下载
上一篇:一种医用注射器针头装配设备
下一篇:一种(S)-2,6-二氨基-4,5,6,7-四氢苯并噻唑*L-酒石酸盐的碱析方法

网友询问留言

已有0条留言

还没有人留言评论。精彩留言会获得点赞!

精彩留言,会给你点赞!

技术分类